- Home
- LLY vs MRK Comparison
LLY vs MRK Comparison
Compare LLY & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | MRK |
|---|---|---|
| Founded | 1876 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 317.8B |
| IPO Year | 2007 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LLY | MRK |
|---|---|---|
| Price | $1,281.49 | $152.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 17 |
| Target Price | ★ $1,218.84 | $125.59 |
| AVG Volume (30 Days) | 2.0M | ★ 6.0M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | 0.81% | ★ 3.06% |
| EPS Growth | ★ 95.99 | 8.01 |
| EPS | ★ 16.19 | N/A |
| Revenue | ★ $65,179,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $27.15 | $3.61 |
| Revenue Next Year | $16.04 | $5.41 |
| P/E Ratio | $75.77 | ★ N/A |
| Revenue Growth | ★ 44.70 | 1.31 |
| 52 Week Low | $694.23 | $77.58 |
| 52 Week High | $1,249.45 | $137.98 |
Technical Indicators
Market Signals| Indicator | LLY | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 82.28 |
| Support Level | $978.43 | $113.32 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 41.35 | 3.51 |
| MACD | 5.67 | 1.39 |
| Stochastic Oscillator | 89.71 | 97.81 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).